Document:

Consent

 EXHIBIT 10.130 
 CONSENT 
 This Consent (the “Consent”), dated as of October 31, 2006, is
entered into by and among Accentia Biopharmaceuticals, Inc., a Florida corporation (“Accentia”), Analytica International, Inc. (formerly The Analytica Group, Inc.), a Florida corporation (“Analytica”), Biolender,
LLC, a Delaware limited liability company (“Biolender”), TEAMM Pharmaceuticals, Inc., a Florida corporation (“TEAMM” and together with Accentia, Analytica, TEAMM and Biolender, the “Accentia Credit
Parties” and each, an “Accentia Credit Party”), and Laurus Master Fund, Ltd., a Cayman Islands company (“Laurus”), in connection with (i) that certain Note and Warrant Purchase Agreement (as amended,
modified or supplemented from time to time, the “Purchase Agreement” and, together with the Related Agreements and Security Documents, each as defined therein, the “Biovest Funding Documents”), dated as of
March 31, 2006, by and between Biovest International, Inc., a Delaware corporation (“Biovest”, together with the Accentia Credit Parties, the “Credit Parties” and each, a “Credit Party”),
certain Subsidiaries of Biovest and Laurus, (ii) that certain Securities Purchase Agreement, dated as of April 29, 2005, by and between Accentia and Laurus (as amended, modified or supplemented from time to time, the “Accentia
Purchase Agreement” and, together with the Related Agreements referred to therein, the “Accentia Purchase Documents”) and (iii) that certain Security Agreement, dated as of April 29, 2005, and amended and restated
as of February 13, 2006, by and between Accentia, Analytica, TEAMM and Laurus (as amended, modified or supplemented from time to time, the “Accentia Security Agreement” and, together with the Ancillary Agreements referred to
therein, the “Accentia Security Documents” and together with the Accentia Purchase Documents, the “Accentia Funding Documents” and, together with the Biovest Funding Documents, the “Laurus Funding
Documents”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Laurus Funding Documents, as applicable. 
 WHEREAS, the Credit Parties wish to obtain Laurus’ consent to the following proposed business transactions and agreements: (i) the sale by Accentia of certain or all of its rights in the Xodol product line;
(ii) the sale by Accentia of its rights in the Histex product line; (iii) the sale by Accentia of the clinical trial division of IMOR-Analytica GmbH, a corporation organized under the laws of Germany and wholly-owned subsidiary of
Analytica (“IMOR”); (iv) the sale by Accentia to Biovest of Accentia’s ownership interest in Biolender LLC, (v) an increase of up to $3.1 million dollars in aggregate principal amount of inter-company loans from
Accentia to Biovest; (vi) certain modifications to Accentia’s business plan relating specifically to the reduction in the amount of Accentia’s voting equity ownership percentage of Biovest, the realingment of the focus and business
emphasis of Accentia’s specialty pharmaceuticals sales division on oncology products and pain products and the role to be maintained by Accentia in the commercializing Biovest’s biologic products; (vii) termination of the Biologic
Products Commercialization Agreement, dated as August 17, 2004 between Accentia and Biovest (as amended, modified or supplemented from time to time, the “Commercialization Agreement”) and the grant by Biovest to Accentia of a
passive 19.5% royalty to be paid by Biovest to Accentia on the sale of biologic products (“Royalty Grant”); and (viii) termination of the anti-dilution/first right of refusal right Agreement between Accentia and Biovest, dated
as of June 16, 2003 (the “Right of Refusal Agreement”) (collectively the “Proposed Transactions”); 
  

 WHEREAS, each Credit Party acknowledges that the Proposed Transactions require Laurus’s consent
under the Laurus Funding Documents; 
 WHEREAS, Laurus has agreed to consent to the Proposed Transaction on the terms and conditions set
forth herein; 
 WHEREAS, Accentia has agreed to issue, grant and deliver to Laurus the Additional Warrant (as defined below). 
 NOW, THEREFORE, in consideration of the above, and for other good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the parties hereto agree as follows: 
 1. Laurus hereby consents to: 
  

	 	a.	the proposed sale by Accentia of certain or all of its rights in the Xodol product line in an arm’s-length transaction negotiated in good faith by the parties (the
“Xodol Sale”), the sale by Accentia of its rights in the Histex product line in an arm’s-length transaction negotiated in good faith by the parties (the “Histex Sale”); and the sale by Accentia of the clinical
trial division of IMOR in an arm’s-length transaction negotiated in good faith by the parties (the “IMOR Sale” and together with the Xodol Sale and the Histex Sale, the “Accentia Sales” and each, an
“Accentia Sale”), provided that, on each date on or after the Consent Effective Date upon which Accentia or any of its Subsidiaries receives Net Sale Proceeds (as defined below) from any Accentia Sale, an amount equal to fifty
percent (50%) of the Net Sale Proceeds (notwithstanding that certain of such assets may constitute TEAMM Transactions as defined in the Overadvance Side Letter, dated as of July     , 2006) as a mandatory repayment of
outstanding Obligations under the Accentia Funding Documents in the following manner (i) accrued and unpaid interest and fees (including any applicable prepayment fees) and (ii) outstanding principal. “Net Sale Proceeds”
shall mean for any sale of assets, the gross cash proceeds (including any cash received by way of deferred payment pursuant to a promissory note, receivable or otherwise, but only as and when received) received from any sale of assets, net of
(i) reasonable transaction costs (including, without limitation, any underwriting, brokerage or other customary selling commissions and reasonable legal, advisory and other fees and expenses, including consent, title, filing and recording
expenses, associated therewith) and payments of unassumed liabilities relating to the assets sold at the time of, or within 30 days after, the date of such sale, (ii) the amount of such gross cash proceeds required to be used to repay any
indebtedness or other outstanding obligation (other than indebtedness of Laurus pursuant to the Laurus Funding Documents) related to such sale (if any), and (iii) the estimated marginal increase in income taxes which will be payable by
Accentia’s consolidated group with respect to the fiscal year in which the sale occurs as a result of such sale; 

  

 2 

	 	b.	the sale by Accentia to Biovest of all of Accentia’s equity ownership interest in Biolender, LLC in exchange for the issuance by Biovest to Accentia of no less than 10,000,000
shares of its common stock, par value $0.01; 

  

	 	c.	(I) an increase by up to $3.1 million dollars (the “$3.1M Increase”) of the inter-company loan (the “Accentia Inter-Company Loan”) extended by
Accentia to Biovest and (II) to release to Biovest as part of NMTC Financing Tranche 2 all amounts remaining in the Restricted Account (as defined in the Purchase Agreement); provided that, (i) the $3.1M Increase shall be used by Biovest in
connection with Tranche #2 of Biovest’s NMTC financing as evidenced by NMTC Finanicng closing documents dated no later than November 15, 2006, by and among AutovaxidID, Inc., a Florida corporation (“AutovaxID”), Biolender,
LLC and Biovest (the “NMTC Financing Tranche 2”), (ii) after giving effect to the $3.1M Increase, the Accentia Inter-Company Loan shall be in principal amount of no more than $9.6 million (iii) the NMTC Financing Tranche 2
shall close on or prior to November 15, 2006, (iv) Biovest shall receive cash proceeds from the NMTC Financing Tranche 2 of no less than $5,500,000, (v) Biovest shall use no more than $1.1 million from the cash proceeds of the NMTC
Financing Tranche 2 to repay the Accentia Inter-Company Loan, (vi) the NMTC Financing Tranche 2 and the Accentia Inter-Company Loan shall be subordinated in right of payment and priority to the Obligations as defined in the Laurus Funding
Documents in form and substance reasonably satisfactory to Laurus, and (vii) the documentation evidencing such NMTC Financing Tranche 2, $3.1M Increase and Accentia Inter-Company Loan shall be in form and substance satisfactory to Laurus and
shall in no way adversely impact Laurus’ rights and remedies under the Laurus Funding Documents; 

  

	 	d.	the termination by Accentia and Biovest of the Commercialization Agreement between Accentia and Biovest as part of the establishment of a passive 19.5% royalty entitlement; provided
that, Accentia receives simultaneous with such termination as consideration therefore a minimum of five million (5,000,000) duly authorized and issued shares of Biovest common stock, par value $0.01 and the Royalty Grant; provided further that,
the documentation pertaining to the aforesaid is in form and substance satisfactory to Laurus and shall in no way adversely impact Laurus’ rights and remedies under the Accentia Funding Documents; and 

  

	 	e.	the termination of Accentia’s anti-dilution/first right of refusal Agreement with Biovest provided that Accentia receives as consideration therefor a minimum of five million
(5,000,000) duly authorized and issued shares of Biovest common stock, par value $0.01. 

 2. Laurus hereby waives its
Financing Right of First Refusal contained in the Purchase Agreement with respect to the NMTC Financing Tranche 2. 
  

 3 

 3. Accentia hereby issues a seven year warrant (the “Additional Warrant”) to Laurus to
purchase 10,000,000 shares of outstanding common stock of Biovest owned by Accentia with an exercise price of $0.01 per share acquired thereunder, such Additional Warrant to be in the form attached hereto as Exhibit A. In connection with the
issuance by Accentia of the Additional Warrant, subject to the terms and conditions of the Additional Warrant, Accentia hereby agrees to cause the Biovest transfer agent (the “Transfer Agent”) to issue and deliver to Laurus (or its
designee), upon receipt of an exercise notice in respect of the Additional Warrant and the original Biovest stock certificate pledged by Accentia to Laurus representing not less than the number of Biovest shares being exercised in the exercise
notice and otherwise held by Laurus as collateral and an appropriate stock power executed by Accentia, (i) a duly executed stock certificate issued in the name of “Laurus Master Fund, Ltd.” for such number of shares of Biovest common
stock set forth in the applicable exercise notice (to the extent that the aggregate of all such exercise notices issued under the Additional Warrant are not in excess of 10,000,000 shares (subject to adjustments as set forth in the Additional
Warrant)) which shares shall have the appropriate SEC restrictive legend unless Transfer Agent receives an opinion from Accentia’s counsel that such legend is not required and (ii) a duly executed replacement stock certificate standing in
the name of Accentia evidencing the shares of Biovest common stock remaining under the stock certificate exchanged by Laurus and not otherwise transferred in the name of Laurus Master Fund, Ltd; provided, that Biovest will cause the Transfer Agent
to acknowledge in writing its agreement with the foregoing and that no additional approval shall be required of Accentia and/or Biovest to effect the foregoing issuances (the “Transfer Agent Acknowledgement”). 
 4. Each consent set forth herein shall be effective as of the first date (the “Consent Effective Date”) when (i) each Credit Party
shall have executed and delivered to Laurus (or its designee) its respective counterpart to this Consent; (ii) Accentia shall have delivered to Laurus (or its designee) a duly executed and witnessed Additional Warrant in the form attached
hereto as Exhibit A; (iii) Accentia shall have agreed to deliver to Laurus (or its designee) within five business days following closing of the transactions described in Section 1(b), (d) and (e) above, the original stock
certificates evidencing all equity interests held by Accentia in Biovest (to the extent not already delivered), together with duly executed undated stock powers executed in blank, as well as a duly executed Transfer Agent Acknowledgement;
(iv) AutovaxID shall have agreed that upon Closing of the NMTC Financing Tranche 2 it will deliver to Laurus (or its designee) a Joinder Agreement in the form attached hereto as Exhibit B; and (v) each of AutovaxID, Biovest,
Accentia and St. Louis New Markets Tax Credit Fund-II, LLC shall have agreed that upon Closing of the NMTC Financing Tranche 2 it will deliver to Laurus (or its designee) a Subordination Agreement in form attached hereto as Exhibit C or in
form and substance approved by Laurus and the parties thereto (the “St. Louis NMTC Subordination Agreement”). 
 5. Accentia and
Biovest hereby agree to deliver to Laurus (or its designee) each document evidencing the Proposed Transactions and the NMTC Financing Tranche 2, including without limitation, the St. Louis NMTC Subordination Agreement, each duly executed and
delivered by the respective parties thereto. 
  

 4 

 6. Except as specifically set forth in this Consent, there are no amendments, modifications or waivers to
the Laurus Funding Documents, and all of the forms, terms and provisions of the Laurus Funding Documents remain in full force and effect. 
 7. On the date hereof, after giving effect to this Consent, each Credit Party hereby represents and warrants to Laurus, as applicable, that (i) no Event of Default exists under the Laurus Funding Documents, (ii) all
representations, warranties and covenants made by the Credit Parties in connection with the Laurus Funding Documents are true, correct and complete and (iii) all of the Credit Parties’ covenant requirements have been met. 
 8. Each of Accentia and Biovest agree to file with the SEC, to the extent required by applicable law and/or regulation, public disclosure of this Consent
and the matters address herein in the appropriate form required by the SEC for such filing within four (4) days of the date hereof. 
 9. This Consent shall be binding upon the parties hereto and their respective successors and permitted assigns and shall inure to the benefit of and be enforceable by each of the parties hereto and their respective successors and permitted
assigns. THIS CONSENT SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH AND GOVERNED BY THE LAW OF THE STATE OF NEW YORK This Consent may be executed in one or more counterparts, each of which shall be deemed an original but all of
which shall constitute one instrument. Execution of this Consent and delivery of a signature page by facsimile or email shall bind and constitute valid delivery of this Consent by the sending executing party to be followed by originals signed by the
executing party. 
 [Balance of Page Left Intentionally Blank] 
  

 5 

 IN WITNESS WHEREOF, each Credit Party and Laurus have caused their duly authorized representatives
to duly execute this Consent on the date as first written above. 
  

			
	LAURUS MASTER FUND, LTD.
		
	By:	 	/s/ Eugene Grin
	Name:	 	Eugene Grin
	Title:	 	Director
	
	ACCENTIA BIOPHARMACEUTICALS, INC.
		
	By:	 	/s/ Francis E. O’Donnell, Jr.
		 	Name: Francis E. O’Donnell, Jr.
		 	Title: CEO
	
	 BIOLENDER, LLC
 By Biovest
International, Inc., its managing member

		
	By:	 	/s/ Steven Arikian
		 	Name: Steven Arikian
		 	Title: Chairman & CEO
	
	ANALYTICA INTERNATIONAL, INC.
		
	By:	 	/s/ Steven Arikian
		 	Name: Steven Arikian
		 	Title: Chairman & CEO
	
	TEAMM PHARMACEUTICALS, INC.
		
	By:	 	/s/ Francis E. O’Donnell, Jr.
		 	Name: Francis E. O’Donnell, Jr.
		 	Title: CEO

  

 EXHIBIT A 
 WARRANT 
  

 7 

 EXHIBIT B 
 AUTOVAXID, INC. TO BIOVEST FUNDING DOCUMENTS JOINDER 
  

 8 

 EXHIBIT C 
 NEW MARKET TAX CREDIT FUND II, LLC SUBORIDNATION AGREEMENT 
  

 9Warrant

 EXHIBIT 10.131 
 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THIS WARRANT AND THE COMMON STOCK
ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS WARRANT UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF
COUNSEL REASONABLY SATISFACTORY TO ACCENTIA BIOPHARMACEUTICALS, INC. AND BIOVEST INTERNATIONAL, INC. THAT SUCH REGISTRATION IS NOT REQUIRED. 
  

			
	 W-        
	  	Warrant to Purchase up to 10,000,000
		  	Shares of Common Stock of
		  	Biovest International, Inc.

 WARRANT 
 Issue Date: October 31, 2006 
 ACCENTIA BIOPHARMACEUTICALS, INC., a corporation organized under the
laws of the State of Florida (the “Company”), hereby certifies that, for value received, LAURUS MASTER FUND, LTD., or assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company (as
defined herein) from and after the Issue Date of this Warrant and at any time or from time to time before 5:00 p.m., New York time, through the close of business October 30, 2012 (the “Expiration Date”), up to 10,000,000 of fully paid
and nonassessable shares of common stock, $0.01 par value per share, of Biovest International, Inc. (“Biovest”) which are, on the date hereof, issued and outstanding and owned of record and beneficially by the Company at the Exercise Price
per share (as defined below) (the “Warrant Shares”). The number and character of the Warrant Shares and the Exercise Price per share under this Warrant are subject to adjustment as provided herein. 
 The Holder agrees to duly execute and deliver the Investment Representation Statement attached hereto as Exhibit C (the “Investment
Representation Statement”) to the Company on or before the date hereof and acknowledges that the Company is issuing this Warrant in reliance on the representations set forth in the Investment Representation Statement. 
 As used herein, the following terms, unless the context otherwise requires, have the following respective meanings: 
 (a) The term “Common Stock” means (i) Biovest’s Common Stock, par value $0.01 per share; and (ii) any other
securities into which or for which any of the securities described in the preceding clause (i) may be converted or exchanged pursuant to a plan of recapitalization, reorganization, merger, sale of assets or otherwise. 
 (b) The term “Company” shall mean Accentia Biopharmaceuticals, Inc. 
  

 (c) The “Exercise Price” applicable under this Warrant shall be $0.01 per
share. 
 1. Exercise of Warrant. 
 1.1. Number of Shares Issuable upon Exercise. From and after the date hereof through and including the Expiration Date, the Holder shall be entitled to receive, upon exercise of this Warrant in whole or in part, by delivery of an
original or fax copy of an exercise notice in the form attached hereto as Exhibit A (the “Exercise Notice”), Warrant Shares, subject to adjustment pursuant to Section 4. 
 1.2. Company Acknowledgment. The Company will, at the time of the exercise of this Warrant, upon the request of the Holder, acknowledge in writing
its continuing obligation to afford to such holder any rights to which such holder shall continue to be entitled after such exercise in accordance with the provisions of this Warrant. If the Holder shall fail to make any such request, such failure
shall not affect the continuing obligation of the Company to afford to such holder any such rights. 
 2. Procedure for Exercise.

 2.1. Delivery of Stock Certificates, Etc., on Exercise. The Company agrees that the Warrant Shares purchased upon exercise of this
Warrant shall be deemed to be issued to the Holder as the record owner of such shares as of the close of business on the date on which this Warrant shall have been surrendered and payment shall have been made for such shares in accordance herewith.
As soon as practicable after the exercise of this Warrant in full or in part, and in any event within three (3) business days thereafter, the Company at its expense (including the payment by it of any applicable issue taxes) will cause to be
issued in the name of and delivered to the Holder, or as such holder (upon payment by such holder of any applicable transfer taxes) may direct in compliance with applicable securities laws, a certificate or certificates for the number of duly and
validly issued, fully paid and nonassessable Warrant Shares. Notwithstanding anything to the contrary set forth herein or in any other agreement, in connection with any exercise by the Holder under this Warrant, the Holder may deliver to the
transfer agent of the Common Stock shares of common stock of Biovest issued in the name of the Company and pledged by the Company to the Holder as collateral in exchange for Warrant Shares, and the transfer agent shall be permitted to issue to
Holder such Warrant Shares set forth in the exercise notice without requiring further approval from the Company or Biovest. Any shares not so exchanged for Warrant Shares shall be returned to Holder to retain as collateral (together with a new duly
executed undated stock power executed in blank). 
 2.2. Exercise. 
 (a) Payment shall be made in cash or by certified or official bank check payable to the order of the Company equal to the applicable aggregate Exercise
Price and the Holder shall thereupon be entitled to receive the number of duly authorized, validly issued, fully-paid and non-assessable Warrant Shares determined as provided herein. 
  

 2 

 3. Effect of Reorganization, Etc.; Adjustment of Exercise Price. 
 3.1. Reorganization, Consolidation, Merger, Dissolution, Stock Split, Dividend or Other Distribution, Etc. In case at any time or from time to
time, Biovest shall (a) effect a reorganization, (b) consolidate with or merge into any other person, (c) effect a stock split, dividend or other distribution or (c) transfer all or substantially all of its properties or assets
to any other person under any plan or arrangement contemplating the dissolution of Biovest, then, in each such case, Holder shall upon Exercise of this Warrant be entitled to purchase the resulting security or property received by the Company in
exchange or as a result of the Warrant Shares. 
 3.2. Continuation of Terms. Upon any reorganization, consolidation, merger or
transfer (and any dissolution following any transfer) of Biovest referred to in this Section 3, this Warrant shall continue in full force and effect and the terms hereof shall be applicable to the other securities and property receivable on or
as a result of the Warrant Shares after the consummation of such reorganization, consolidation or merger or the effective date of dissolution following any such transfer, as the case may be. 
 4. Reservation of Warrant Shares Issuable on Exercise of Warrant. The Company will at all times reserve and keep available, solely for issuance
and delivery on the exercise of this Warrant, Warrant Shares from time to time issuable on the exercise of this Warrant. 
 5. Assignment;
Exchange of Warrant. Subject to compliance with applicable securities laws, this Warrant, and the rights evidenced hereby, may be transferred by any registered holder hereof (a “Transferor”) in whole or in part. On the surrender for
exchange of this Warrant, with the Transferor’s endorsement in the form of Exhibit B attached hereto (the “Transferor Endorsement Form”) and together with evidence reasonably satisfactory to the Company demonstrating compliance with
applicable securities laws, which shall include, without limitation, the provision of a legal opinion from the Transferor’s counsel (at the Company’s expense) that such transfer is exempt from the registration requirements of applicable
securities laws, the Company at its expense (but with payment by the Transferor of any applicable transfer taxes) will issue and deliver to or on the order of the Transferor thereof a new Warrant of like tenor, in the name of the Transferor and/or
the transferee(s) specified in such Transferor Endorsement Form (each a “Transferee”), calling in the aggregate on the face or faces thereof for the number of shares of Common Stock called for on the face or faces of the Warrant so
surrendered by the Transferor. 
 6. Replacement of Warrant. On receipt of evidence reasonably satisfactory to the Company of the
loss, theft, destruction or mutilation of this Warrant and, in the case of any such loss, theft or destruction of this Warrant, on delivery of an indemnity agreement or security reasonably satisfactory in form and amount to the Company or, in the
case of any such mutilation, on surrender and cancellation of this Warrant, the Company at its expense will execute and deliver, in lieu thereof, a new Warrant of like tenor. 
 7. Registration Rights. The Holder has been granted certain piggy-back registration rights by the Company and Biovest. These registration rights
are set forth in a Consent entered into by the Company, Biovest, certain other parties and Holder dated as of the date hereof, as the same may be amended, modified and/or supplemented from time to time. 
  

 3 

 8. Maximum Exercise. Notwithstanding anything herein to the contrary, in no event shall the Holder
be entitled to exercise any portion of this Warrant in excess of that portion of this Warrant upon exercise of which the sum of (1) the number of shares of Common Stock beneficially owned by the Holder and its Affiliates (other than shares of
Common Stock which may be deemed beneficially owned through the ownership of the unexercised portion of the Warrant or the unexercised or unconverted portion of any other security of the Holder subject to a limitation on conversion analogous to the
limitations contained herein) and (2) the number of shares of Common Stock issuable upon the exercise of the portion of this Warrant with respect to which the determination of this proviso is being made, would result in beneficial ownership by
the Holder and its Affiliates of any amount greater than 4.99% of the then outstanding shares of Common Stock (whether or not, at the time of such exercise, the Holder and its Affiliates beneficially own more than 4.99% of the then outstanding
shares of Common Stock). As used herein, the term “Affiliate” means any person or entity that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a person or entity, as
such terms are used in and construed under Rule 144 under the Securities Act. For purposes of the proviso to the second preceding sentence, beneficial ownership shall be determined in accordance with Section 13(d) of the Securities Exchange Act
of 1934, as amended, and Regulations 13D-G thereunder, except as otherwise provided in clause (1) of such proviso. The limitations set forth herein (x) may be waived by the Holder upon provision of no less than sixty one (61) days
prior notice to the Company and (y) shall automatically become null and void following notice to the Company upon the occurrence and during the continuance of an Event of Default (as defined in the Note referred to in the Note and Warrant
Purchase Agreement dated as of the date hereof among the Holder and the Company (as amended, modified, restated and/or supplemented from time to time, the “Purchase Agreement”)). 
 9. Transfer on the Company’s Books. Until this Warrant is transferred on the books of the Company, the Company may treat the Holder as the
absolute owner of the Warrant and treat the Company as the absolute owner of the Warrant Shares for all purposes, notwithstanding any notice to the contrary. 
 10. Notices, Etc. All notices and other communications from the Company to the Holder and from the Holder to the Company shall be mailed by first class registered or certified mail, postage prepaid, at such
address as may have been furnished to the Company in writing by such holder or, until any such holder furnishes to the Company an address, then to, and at the address of, the last Holder who has so furnished an address to the Company. 
 11. Miscellaneous. This Warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by
the party against which enforcement of such change, waiver, discharge or termination is sought. THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAWS.
ANY ACTION BROUGHT CONCERNING THE TRANSACTIONS CONTEMPLATED BY THIS WARRANT SHALL BE BROUGHT ONLY IN THE STATE COURTS OF NEW YORK OR IN THE FEDERAL COURTS LOCATED IN THE STATE OF NEW YORK; PROVIDED, HOWEVER, THAT THE HOLDER MAY CHOOSE TO WAIVE THIS
PROVISION AND BRING AN ACTION OUTSIDE THE STATE OF NEW YORK. The individuals executing this Warrant on behalf of the Company agree to submit to the jurisdiction 
  

 4 

 of such courts and waive trial by jury. The prevailing party shall be entitled to recover from the other party its
reasonable attorneys’ fees and costs. In the event that any provision of this Warrant is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict
therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of this Warrant. The
headings in this Warrant are for purposes of reference only, and shall not limit or otherwise affect any of the terms hereof. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any
other provision hereof. The Company acknowledges that legal counsel participated in the preparation of this Warrant and, therefore, stipulates that the rule of construction that ambiguities are to be resolved against the drafting party shall not be
applied in the interpretation of this Warrant to favor any party against the other party. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK;
SIGNATURE PAGE FOLLOWS] 
  

 5 

 IN WITNESS WHEREOF, the Company has executed this Warrant as of the date first written above. 

 

							
		 		 	ACCENTIA BIOPHARMACEUTICALS,
INC.
				
	 WITNESS:
	 		 		 	
		 		 	By:	 	 /s/ Francis E. O’Donnell, Jr.
  

		 		 	Name:	 	Francis E. O’Donnell, Jr.
	 /s/Steven Arikian
  
	 		 	Title:	 	CEO

  

 6 

 Exhibit A 
 FORM OF SUBSCRIPTION 
 (To Be Signed Only On Exercise Of Warrant) 
  

	TO:	Accentia                                     
         Biopharmaceuticals,                            
                            Inc. 

 Attention:      Chief Financial Officer 
 The undersigned, pursuant to the provisions set forth in the attached Warrant, hereby irrevocably elects to purchase (check applicable box): 
                                      
        Warrant Shares 
 The undersigned herewith makes payment of the full Exercise Price for
such shares at the price per share provided for in such Warrant, which is $            . Such payment takes the form of: 
 The undersigned requests that the certificates for such shares be issued in the name of, and delivered to
                                 whose address is
                                        
            . 
 The undersigned represents and warrants that it is an
“Accredited Investor,” as such term is defined in Rule 501(a) of Regulation D promulgated under the Securities Act of 1933. 
 The
undersigned represents and warrants that all offers and sales by the undersigned of the securities issuable upon exercise of the within Warrant shall be made pursuant to registration of the Common Stock under the Securities Act of 1933, as amended
(the “Securities Act”) or pursuant to an exemption from registration under the Securities Act. 
  

									
	Dated:	 	  	  	 	 	  
		 		  		 	(Signature must conform to name of Holder as specified on the face of the Warrant)
		 		  		 		  	
		 		  		 	Address: 	  	  
		 		  		 		  	  

  

 A-1 

 Exhibit B 
 FORM OF TRANSFEROR ENDORSEMENT 
 (To Be Signed Only On Transfer Of Warrant) 
 For value received, the undersigned hereby sells, assigns, and transfers unto the person(s) named below under the heading “Transferees” the
right represented by the within Warrant to purchase the number of Warrant Shares opposite the name(s) of such person(s) and appoints each such person Attorney to transfer its respective right on the books of the Company with full power of
substitution in the premises. 
  

													
	Transferees	 	 	  	Address	 	 	  	 	 	 	  	Warrant to
purchase The
Number of
Warrant
Shares
set forth
below
		 		  		 		  		 		  	
	  	 		  	  	 		  	  	 		  	  
	  	 		  	  	 		  	  	 		  	  
	  	 		  	  	 		  	  	 		  	  
	  	 		  	  	 		  	  	 		  	  

  

									
		 		  		 		 	
	Dated:	 	  	  	 	 	  
		 		  		 	(Signature must conform to name of Holder as specified on the face of the Warrant)
		 		  		 		 	
		 		  		 	Address: 	 	  
		 		  		 		 	  
		 		  		 		 	
		 		  		 		 	
		 		  		 	SIGNED IN THE PRESENCE OF:
		 		  		 		 	
		 		  		 	  
		 		  		 	(Name)
	 ACCEPTED AND AGREED:
	  		 		 	
	 [TRANSFEREE]
	  		 		 	
		  		 		 	
	  	  		 		 	
	(Name)	  		 		 	

  

 B-1 

 Exhibit C to Warrant 
 INVESTMENT REPRESENTATION STATEMENT 
 Shares of Common Stock of 
 BIOVEST INTERNATIONAL, INC. 
 In connection
with the purchase through the exercise of a warrant of the above-listed shares of Common Stock (the “Securities”), the undersigned hereby represents to Accentia Biopharmaceuticals, Inc. (the “Company”) as follows: 
 The Securities will be acquired for investment for its own account, not as a nominee or agent, and not with a view to the sale or distribution of any
part thereof, and the undersigned has no present intention of selling, granting participation in or otherwise distributing the same in violation of the Securities Act of 1933, as amended (the “Act”). 
 The undersigned understands that the Securities issuable upon exercise of the Warrant at the time of issuance may not be registered under the Act, and
applicable state securities laws, on the ground that the issuance of such securities is exempt pursuant to Section 4(2) of the Act and/or Regulation D - Rule 506 thereunder and state law exemptions relating to offers and sales not by means of a
public offering, and that the Company’s reliance on such exemptions is predicated on the undersigned’s representations set forth herein. 
 The undersigned understands that the Securities have not been registered under the Securities Act or applicable state securities laws, and may be offered and sold under an exemption from registration provided by such laws and the rules and
regulations thereunder. The undersigned agrees that in no event will it make a disposition of the Securities unless and until the Securities are registered under the Act or sold pursuant to Rule 144, or it shall have furnished the Company and
the Issuer with an opinion of counsel satisfactory to the Company and the Issuer and their respective counsel to the effect that registration of the Securities is not required to effect such disposition. 
 No representations or promises have been made concerning the marketability or value of the Securities. 
 The representations and warranties made by the undersigned herein are made by the undersigned with the intent that they be relied upon by the Company in
determining the compliance of issuance of the shares with exemptions from federal or state securities laws. 
 The following information is
needed to determine whether issuance of the Securities by the Company is legally permitted. 
 The undersigned understands that this
questionnaire is to enable the Company to discharge its responsibilities under federal and state securities laws and that the Company will 
  

 B-1 

 rely on the information contained herein. Accordingly, the undersigned represents and warrants to the Company that:

 (a) the information contained herein is complete and accurate and may be relied on by the Company; and 
 (b) the undersigned is an “Accredited Investor” within the meaning of Rule 501 of Regulation D of the Act, as presently in effect, because the
undersigned is a corporation or partnership, not formed for the specific purpose of acquiring the securities, with total assets in excess of $5,000,000, or is entity in which all of the equity owners are accredited investors. 
  

									
	 Dated:
	 	  
  
	 		 	  
  

		 		 		 	(Typed or Printed Name)
					
		 		 		 	  
 By:
	 	  
  

		 		 		 		 	(Signature)
				
		 		 		 	  
  

		 		 		 	(Title)

  

 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00115-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00115-of-00352.parquet"}]]